Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you bears for coming out of hibernation and scarying up some cheap shares target .33.
btw any mention of how many new customers in February, I know the count in Jan was up 10 %
Leap Year ! An extra day to load !
financials cleaner and a 7.1billion market to tap
i'd say that's ground worth mining
CHEERS well they fixed the leaky bucket financials ,customers growing, who doesn't like a growing company
guess somebody did not get the memo
http://client.irwebkit.com/gbscience/news/2437216
the molecular diagnosis business is guestimated to be 7.1 Billion. There is your potential
probably buy out partner deal from where I sit
Molecular diagnostics are estimated to be a 7 .1 Billion industry next year
We have patents!
products
and a growing customer base
Ha ha Picasso showed up with a red paint brush,but seriously just the fact they got any money is a miracle and we know financiers don't invest in miracles so they must have something besides fairy dust
Goldman Fails To Get $2 Billion LBO Deal Done Even At Double-Digit Yields http://www.zerohedge.com/news/2016-02-25/rip-ma-boom-goldman-fails-get-2-billion-lbo-deal-done-even-double-digit-yields …
sehr gut you noticed I got tired of seeing red had to post
however anything less than a dollar is a STEAL
no mention of the patents
and the fact they are hiring
makes me kaufen kaufen kaufen
:-]
.1949 after hrs
I think we're in better shape
and the market will take notice
especially with FDA looming
yes upward slant and the tide is turning even my .27s are looking good the vix is high here and the stock can move up on a whim unexpectedly upwards however with fda tickets new possibilities and probabilities higher if postive blue skies as bidding wars ensue for the 7.1 billion market next year in the molecular diagnosis where gbsn is considered a player
FDA events are exciting around this company
gets hotter with time factor
today it's not exploding for me I just added however I hate to miss an explosion for their explosive effect on my account....GBSN Kaboom soon
8.7 Billion,very nice I'm liking the big picture
looking like a turna round play
now this is some news,lots of possibilities thanks
Mutual funds make my mouth water they'll be back into growth and the Fang are overbought and getting long in the tooth
and this little juicy morsel if true on stocktwits
confirms my thoughts exactly
sweet deal for shareholders and others might bid as well for the patents
I think with the FDA a buyout or partnership w/ a major player
Strangely enough I'm not worried having paid 60 x what the shares are selling for now,these are very special and a bargain so I am adding to my stake it's looking longer term now that the customer base is growing,fulfilling a met need is always gratifying and win win so onward and upward. Also the financing is somewhat senior to the dilutive mess it has been. Demand equalling supply that way,a nice base for a takeoff on any number of catalysts or none whatsoever remeber last week it shot up on nothing,well at least it's going the right way for a change
7.6 Billion
great play almost as good as GBSN
we could be a big slice of this pie
"With molecular diagnostics projected to grow to a $7.6 billion industry by 2017 (Kalorama) and surpass $8 billion by 2020 (Grand View Research)"
I stuck to my plan and added here.
agreed great opportunity for any starter position and a greater opportunity for the country if it gets to market sooner than later.
Time will tell in the meantime we could be in a Bidding war soon
Great post
They already consider GBSN as a competitor, VIVO says "we are well positioned to capitalize on the migration to molecular testing.
They already consider GBSN as a competitor, VIVO says "we are well positioned to capitalize on the migration to molecular testing.
close enough for me too i just added
one more thing is float 50% short? if true than that plus nakeds plus demand =short squeeze plausibilty
I recall that and your explanation makes sense, could definitely be a reason for record date and we know the bad news has already been announced it's looking pretty for next week,very good indeed Some blue sky weather up ahead and less flipping could be a boon here for sick people who can't afford the high cost of diagnoses and I'm sure the insurance companies will like it and of course the gov is looking nine ways to sunday to decrease the cost of med diagnoses,soon we''l be in the drivers seat. Dollar cost averaging as I accumulate as much as I can afford.not to forget tharanos and e coli chipotle this is a story stock if gbsn can keep this 10 % pace up then dollars aren't far behind.gltu
record date friday please explain
missed that one in my dd
Just 10 % a month sales gain compounded monthly would turn a 100 into 300 I believe
so a 300 % increase in sales woulld surely transmit to the bottom line and a senior debt profile and quite likely in my opinion a buyout
I wonder if this is the tipping point sure feels like it shorts are vociferous again
Great Basin Announces 201 Customers to End January 2016
Great Basin Scientific, Inc. (MM) (NASDAQ:GBSN)
Intraday Stock Chart
Today : Wednesday 3 February 2016
Click Here for more Great Basin Scientific, Inc. (MM) Charts.
Company focuses on under-served hospital laboratories with its easy-to-use, low-cost, and versatile system for molecular diagnostics
Great Basin Scientific, Inc. (NASDAQ:GBSN) announced today that its customer base grew to 201 sites by the end of January, up from 186 at the end of December 2015, continuing the Company’s steady overall growth for its sample-to-result molecular diagnostics platform.
Great Basin’s platform is designed to meet the needs of the small, mid-sized, and critical access hospitals. With limited capital equipment budgets and a need for simplified workflow, smaller hospitals have historically been challenged to adopt molecular diagnostics. Great Basin places their analyzer in hospitals at no cost and delivers ease of use, allowing hospitals to quickly and easily adopt fast and accurate molecular diagnostics.
“I appreciate Great Basin’s products and customer service. They are allowing us little guys to perform testing we never would have been able to before their solution,” said Tabatha Halvorson, Lab Director at Towner County Medical Center in Cando, N.D. and a new Great Basin customer. “The impact this will have on quality of patient care is very exciting.”
Commercially available tests from Great Basin include low-plex tests for Clostridium difficile (C. diff) and Group B Streptococcus (GBS). The Company is awaiting 510(k) clearances from the U.S. Food & Drug Administration (FDA) for their Shiga Toxin Direct Test, which, upon FDA clearance, will be the only stand-alone test to provide CDC-recommended identification of the high-virulence serotype O157 in conjunction with the Shiga toxin-producing E. coli (STEC) detection; and Staph ID/R Blood Culture panel, a direct from whole blood multiplex panel to detect blood sepsis caused by MRSA and other staph species.
“We’re pleased to have reached this milestone and gratified to be able to support hospitals like Towner County Medical Center,” said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin Scientific.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statements regarding the Company’s continuing business efforts related to its products, including but not limited to, assistance of health providers to define a clear treatment path sooner for improved patient outcomes, shorter hospital stays and dollars saved in hospitalization costs per patient, the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases and related statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160203005352/en/
Media:
ICR
Kate Ottavio Kent, 203.682.8276
Kate.Ottavio-Kent@icrinc.com
or
Investor Relations:
ICR
David Clair, 646.277.1266
David.Clair@icrinc.com
tomorrow maybe?
RSSS are not always bad especially when you have a heads up,but I canthink of three companies that fared well in the rs department
AVXL, AEZS, AMDA all recent
but maybe they didn't have onerous debt like death spiral financing
I hear there's a 50 % short interest
theyre on SHO list
FDA approvals pending
I can think of worse bets
could be, cheaper than a super bowl commercial
deals are being brokered probably as we speak
I'll take a buy out at a buck no problem
We believe that the diagnostic testing market is continuing to selectively move away from culture and immunoassay testing to molecular testing for diseases where there is a favorable cost/benefit position for the total cost of health care. While this market is competitive, with molecular companies such as Cepheid and Becton Dickinson and others such as Quidel, Great Basin, Nanosphere, and Alere, we believe we are well positioned to capitalize on the migration to molecular testing
from the Meridian sec filing
no doubt GBSN's time has come